Many stakeholders believe innovation only leads to generating new molecules, but innovation can also come from other areas such as focusing on improving present molecules which are no longer protected by patent.
There is significant untapped potential in Europe to optimise existing therapies and value added medicines represent an opportunity for patients, healthcare providers, payers, industry and the healthcare systems in general.
Come and join us for the first Value Added Medicines Conference in Brussels to learn more about value added medicines and to discuss the current environment, challenges and opportunities in Europe.
– Tackling wasteful spending on health
– Incremental innovation on known molecules – Necessity to address all patient needs?
– Value added medicines – How to capture their value for society
The target audience is policy makers, industry, academics and other stakeholders involved.
The discussion will be on repurposing medicines.